Medicare Rx and the Sequester Impact: Making Headlines, But is There a Commercial Impact?
This article was originally published in RPM Report
Executive Summary
Two large pharmaceutical manufacturers weigh in on whether the sequester is impacting their injectables business. The answer so far: not really. The same story goes for the sequester and Part D, though Lilly is seeing higher than expected Part D discounts in 2013.
You may also be interested in...
Testing Part B Payment Cuts: Sequester Means Providers Get ASP+4%
Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.